Mural Selling General Administrative from 2010 to 2024

MURA Stock   3.44  0.20  5.49%   
Mural Oncology's Selling General Administrative is increasing over the years with slightly volatile fluctuation. Selling General Administrative is expected to dwindle to about 26.2 M. From 2010 to 2024 Mural Oncology Selling General Administrative quarterly data regression line had arithmetic mean of  17,900,913 and r-squared of  0.46. View All Fundamentals
 
Selling General Administrative  
First Reported
2010-12-31
Previous Quarter
30.7 M
Current Value
26.2 M
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mural Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mural Oncology's main balance sheet or income statement drivers, such as Tax Provision of 6.3 M, Depreciation And Amortization of 2 M or Selling General Administrative of 26.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.39. Mural financial statements analysis is a perfect complement when working with Mural Oncology Valuation or Volatility modules.
  
Check out the analysis of Mural Oncology Correlation against competitors.

Latest Mural Oncology's Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Mural Oncology plc over the last few years. It is Mural Oncology's Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mural Oncology's overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Mural Selling General Administrative Regression Statistics

Arithmetic Mean17,900,913
Geometric Mean17,389,064
Coefficient Of Variation27.93
Mean Deviation3,764,661
Median15,548,000
Standard Deviation5,000,185
Sample Variance25T
Range15.2M
R-Value0.68
Mean Square Error14.5T
R-Squared0.46
Significance0.01
Slope760,142
Total Sum of Squares350T

Mural Selling General Administrative History

202426.2 M
202330.7 M
202225.1 M

About Mural Oncology Financial Statements

Mural Oncology stakeholders use historical fundamental indicators, such as Mural Oncology's Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Mural Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mural Oncology's assets and liabilities are reflected in the revenues and expenses on Mural Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mural Oncology plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative30.7 M26.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock:
Check out the analysis of Mural Oncology Correlation against competitors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.03)
Return On Assets
(0.81)
Return On Equity
(1.78)
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mural Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.